Objective: To evaluate the impact of adverse reactions on the clinical outcome in
patients treated for multiresistant tuberculosis treated at the University Hospital João
de Barros Barreto. Methodology: An observational, retrospective cohort study of
cases of multidrug-resistant tuberculosis registered on SITE-TB, which underwent
treatment from January 2010 to December 2015. Results: A total of 152 patients who
presented with a mean age of 40, 2 years old, predominantly male (65.1%), brown
breed (69.1%). The majority of the patients had less than seven years of study
(62.4%) and was concentrated in the metropolitan region of Belém (73.7%), with a
predominance of the unemployed (25%). Significant share presented secondary
resistance (88.2%). Regarding drug use, alcohol use was more frequent (20.4%),
followed by illicit drugs (16.5%) and tobacco (5.3%). The presence of comorbidities
was low (27.6%), and Diabetes Mellitus was the most common (23%). Half of the
patients in the study had adverse reactions and the most significant were arthralgia
(31.6%), epigastric pain (15.1%) and peripheral neuropathy (5.3%). The favorable
clinical outcome was predominant in 77% of the cases. The male gender (26.3%)
presented more unfavorable outcome when compared to the female (17%). Among
the occupations, the unemployed had the highest percentage of unfavorable
outcome (39.5%). Among the patients presenting with comorbidity, the majority
presented a favorable outcome (88.1%). As well as those with adverse effects also
had a more favorable outcome (79.0%), however this data did not reach statistical
significance (p = 0.563). The users of illicit drugs and tobacco showed a higher
frequency of unfavorable outcomes (56.0% and 62.5%, respectively). In contrast,
among alcohol users, the majority had a favorable outcome (54.8%). Conclusion:
Multidrug-resistant tuberculosis remains an important public health problem, with
high frequency, especially among the economically active population. Certain
situations influence the clinical outcome of the treatment contributing to the
dissemination of multidrug-resistant strains.
|
